Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman PR Newswire OXFORD, England, June 26, 2013 OXFORD, England, June 26, 2013 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a global...
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has completed its acquisition of Cephalon, Inc. (NASDAQ: CEPH). The combined company will have a...
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon Inc. (NASDAQ: CEPH) announced today that they received approval from the European Commission to proceed with...
S&P Indices Announces Change to U.S. Index PR Newswire NEW YORK, Oct. 11, 2011 NEW YORK, Oct. 11, 2011 /PRNewswire/ -- TE Connectivity Ltd. (NYSE: TEL) will replace Cephalon Inc. (NASD: CEPH) in...
Zacks Sell List Highlights: Molex, CenturyLink, Blue Nile and Cephalon PR Newswire CHICAGO, Sept. 7, 2011 CHICAGO, Sept. 7, 2011 /PRNewswire/ -- Zacks.com releases details on a group of stocks...
Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 PR...
Cephalon Reported Financial Results for the Second Quarter of 2011 Sales For The Period Were $730 Million Basic Income Per Common Share Increased 31 Percent PR Newswire FRAZER, Pa., Aug. 2, 2011...
The Zacks Analyst Blog Highlights: Mylan, AstraZeneca, Novartis, Cephalon and Moody’s Corp PR Newswire CHICAGO, July 28, 2011 CHICAGO, July 28, 2011 /PRNewswire/ -- Zacks.com announces the list...
Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ PR Newswire FRAZER, Pa., July 21, 2011 FRAZER, Pa., July 21, 2011 /PRNewswire/ -- Cephalon, Inc...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
